Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02682355 · ClinicalTrials.gov registry record
Optimizing Clinical Use of Polymyxin B
A clinical trial, sponsored by Rutgers, The State University of New Jersey.
- Completed
- Registry status
- 155
- Enrollment target
NCT02682355 is a clinical trial that has completed, run by Rutgers, The State University of New Jersey. The registered enrollment target is 155 participants.
The verdict
NCT02682355 has completed, sponsored by Rutgers, The State University of New Jersey.
- COMPLETED
- Registry status
- 155 participants
- Enrollment target
Study Summary
Polymyxin B is already being used extensively in the USA and other parts of the world; its use is likely to rapidly increase due to the greater burden of infections caused by MDR Gram-negative bacteria and the growing awareness of the limitations inherent in the clinical pharmacology of CMS/colistin. Cross resistance exists between the two polymyxins and thus both must be dosed optimally; but the recently generated scientifically-based dosage regimens for CMS/colistin cannot be extrapolated to polymyxin B. It is essential that an adequately powered study is conducted to define the clinical PK/PD/TD relationships of polymyxin B and identify, using next-generation proteomics, biomarkers for early detection of kidney injury. This will allow the development of scientifically-based dosage regimens for various categories of patients and an adaptive feedback control clinical tool for optimized dosing of polymyxin B in future individual patients.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 155 participants |
| Start Date | 2016-02 |
| Est. Completion | 2022-08-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02682355
The ClinicalTrials.gov registry entry for NCT02682355 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 155 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rutgers, The State University of New Jersey, which has 413 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02682355 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02682355 about?
NCT02682355 is a clinical study titled "Optimizing Clinical Use of Polymyxin B". Polymyxin B is already being used extensively in the USA and other parts of the world; its use is likely to rapidly increase due to the greater burden of infections caused by MDR Gram-negative bacteria and the growing awareness of the limitations inherent in the clinical pharmacology of CMS/colistin...
What is the current status of trial NCT02682355?
This trial is currently completed. The enrollment target is 155 participants. The study started on 2016-02. Estimated completion is 2022-08-03.
Who is sponsoring clinical trial NCT02682355?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.